
Roche withdraws checkpoint blocker from the market
Switzerland’s Hoffmann La Roche AG no longer markets its cancer immunotherapy atezolizumab (Tecentriq) for the treatment of urothelial carcinoma in...

HOOKIPA bags US$10m cancer milestone
The Vienna-based arenavirus specialist got the non-dilutive milestone payment for advancing its drug programme HB-700, a novel arenaviral...

Ultra-processed foods increase risk for cancer
According to a long-term data from the UK biobank, high consumption of ultra-processed foods are linked to bad health outcomes such as diabetes,-...

Minaris and LIfT BioSciences collaborate in cell therapy development
LIfT BioSciences wants to start its first-in-human clinical trials with an allogeneic neutrophil progenitor-based cell therapy in first Quartal...

First hints for leukopenia diagnostic in MS
Disease-modifying therapies for multiple sclerosis (MS) may positively influence the composition of the intestinal flora. At least this is what a...

Vitestro raises €12m in Series A financing
California-based Sonder Capital led the Series A financing round alongside existing investors and new private investors. According to...

Lonza collaborates with Asher Biotherapeutics Inc
Asher Biotherapeutics is a developer of targeted immunotherapies for cancer, chronic viral infections and autoimmune disorders. AB248, Asher Bio’s...